PharmaShots | Incisive News in 3 Shots

Subscribe Now

Revance

Revance Submits Supplemental Biologics License Application for Daxxify to Treat Cervical Dystonia

Revance Submits Supplemental Biologics License Application for Daxxify to Treat Cervical Dystonia

October 21, 2022

Revance’s Daxxify (daxibotulinumtoxinA-lanm) Receives the US FDA’s Approval for the Treatment of Glabellar Lines in Adults

Revance’s Daxxify (daxibotulinumtoxinA-lanm) Receives the US FDA’s Approval for the Treatment of Glabellar Lines in Adults

September 8, 2022

PharmaShots Weekly Snapshots (Mar 29 - Apr 02, 2021)

PharmaShots Weekly Snapshots (Mar 29 - Apr 02, 2021)

April 2, 2021

PharmaShots Weekly Snapshot (Jun 01-05, 2020)

PharmaShots Weekly Snapshot (Jun 01-05, 2020)

June 8, 2020

PharmaShots Weekly Snapshot (May 04-08, 2020)

PharmaShots Weekly Snapshot (May 04-08, 2020)

May 11, 2020

Insights+ Key Biosimilars Events of March 2020

Insights+ Key Biosimilars Events of March 2020

April 10, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us